Oragenics ( NYSE: OGEN ) said on Monday it was proposing to offer and sell shares of its common stock (or pre-funded warrants) in a public offering. Shares of OGEN fell 6.02% in extended trading.
The company said that all the securities to be sold in the offering are to be offered by Oragenics. OGEN plans to use the offering to fund the continued development of its ONP-002 product candidate and for general corporate purposes and working capital. More on Oragenics Oragenics climbs 9% amid Phase 2 study, business updates Oragenics files 10K and provides company update Financial information for Oragenics.